• Der Internist · Nov 2021

    Review

    [Atrial fibrillation-Syndromic phenotype in HFpEF or primary disease?]

    • Matthias Mezger, Thomas Stiermaier, Jan-Christian Reil, TilzRoland RichardRRAbteilung für Kardiologie, Angiologie und internistische Intensivmedizin, Universitäres Herzzentrum Lübeck, Lübeck, Deutschland.Deutsches Zentrum für Herz- Kreislauf- Forschung e.V., DZHK Standort Hamburg/Kiel/Lübeck, Lübeck, Deutschla, Evgeny Lyan, Karl-Heinz Kuck, and Ingo Eitel.
    • Abteilung für Kardiologie, Angiologie und internistische Intensivmedizin, Universitäres Herzzentrum Lübeck, Lübeck, Deutschland. matthias.mezger@uksh.de.
    • Internist (Berl). 2021 Nov 1; 62 (11): 1174-1179.

    AbstractAtrial fibrillation and heart failure with preserved left ventricular (LV) ejection fraction (HFpEF) are of high importance in cardiology due to the increasing number of cases. Both diseases can mutually affect each other and important cardiovascular risk factors, e.g. arterial hypertension, diabetes mellitus, obesity and chronic renal insufficiency can be observed with increasing frequency. Currently proven treatment concepts for patients with heart failure and reduced ejection fraction (HFrEF) do not appear to have a comparable prognostic or symptomatic benefit for patients with HFpEF. In addition, there are indications that de novo manifestation of atrial fibrillation in HFpEF patients has been linked to reduced survival. Also, heart and kidney function are negatively affected by atrial fibrillation. Retrospective analyses of patients with HFpEF and atrial fibrillation who had been treated by pulmonary vein isolation could show that interventional treatment of the atrial fibrillation led to an improvement in the New York Heart Association (NYHA) stage and diastolic function. Currently running prospective randomized clinical trials, such as the AMPERE study including patients with HFpEF and atrial fibrillation undergoing pulmonary vein isolation, will hopefully provide reliable prospective randomized data and possibly show an improved symptom control and perhaps also prognostically relevant treatment for HFpEF patients with atrial fibrillation.© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.